S&P 500   3,116.73 (-0.12%)
DOW   27,991.22 (-0.05%)
QQQ   202.35 (-0.28%)
CGC   14.68 (-4.24%)
BABA   186.55 (+0.57%)
T   39.34 (-0.41%)
ACB   2.48 (-9.16%)
F   8.95 (+0.00%)
PRI   130.39 (-0.18%)
BAC   32.87 (-0.18%)
DIS   147.80 (+2.16%)
S&P 500   3,116.73 (-0.12%)
DOW   27,991.22 (-0.05%)
QQQ   202.35 (-0.28%)
CGC   14.68 (-4.24%)
BABA   186.55 (+0.57%)
T   39.34 (-0.41%)
ACB   2.48 (-9.16%)
F   8.95 (+0.00%)
PRI   130.39 (-0.18%)
BAC   32.87 (-0.18%)
DIS   147.80 (+2.16%)
S&P 500   3,116.73 (-0.12%)
DOW   27,991.22 (-0.05%)
QQQ   202.35 (-0.28%)
CGC   14.68 (-4.24%)
BABA   186.55 (+0.57%)
T   39.34 (-0.41%)
ACB   2.48 (-9.16%)
F   8.95 (+0.00%)
PRI   130.39 (-0.18%)
BAC   32.87 (-0.18%)
DIS   147.80 (+2.16%)
S&P 500   3,116.73 (-0.12%)
DOW   27,991.22 (-0.05%)
QQQ   202.35 (-0.28%)
CGC   14.68 (-4.24%)
BABA   186.55 (+0.57%)
T   39.34 (-0.41%)
ACB   2.48 (-9.16%)
F   8.95 (+0.00%)
PRI   130.39 (-0.18%)
BAC   32.87 (-0.18%)
DIS   147.80 (+2.16%)
Log in

Asterias Biotherapeutics Stock Price, Forecast & Analysis (NYSEAMERICAN:AST)

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume136,653 shs
Market Capitalization$2.79 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Asterias Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:AST
Previous SymbolNYSEMKT:AST
CUSIPN/A
CIKN/A
Phone+1-510-4563805

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$2.79 billion
Next Earnings DateN/A
OptionableOptionable

Receive AST News and Ratings via Email

Sign-up to receive the latest news and ratings for AST and its competitors with MarketBeat's FREE daily newsletter.


Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions

What is Asterias Biotherapeutics' stock symbol?

Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."

How were Asterias Biotherapeutics' earnings last quarter?

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) released its quarterly earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The biotechnology company had revenue of $1.75 million for the quarter, compared to the consensus estimate of $2.81 million. View Asterias Biotherapeutics' Earnings History.

Has Asterias Biotherapeutics been receiving favorable news coverage?

News stories about AST stock have been trending very negative on Monday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Asterias Biotherapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Asterias Biotherapeutics.

Who are some of Asterias Biotherapeutics' key competitors?

What other stocks do shareholders of Asterias Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Asterias Biotherapeutics investors own include BioTime (BTX), Synergy Pharmaceuticals (SGYP), Zynerba Pharmaceuticals (ZYNE), CorMedix (CRMD), Amarin (AMRN), Freeport-McMoRan (FCX), Progenics Pharmaceuticals (PGNX), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL) and Amicus Therapeutics (FOLD).

Who are Asterias Biotherapeutics' key executives?

Asterias Biotherapeutics' management team includes the folowing people:
  • Mr. Michael H. Mulroy, CEO, Pres & Director (Age 53)
  • Dr. Edward D. Wirth III, Chief Medical Officer (Age 54)
  • Dr. Katharine E. Spink, Consultant (Age 45)
  • Mr. Stephen L. Cartt, Advisor & Director (Age 56)
  • Mr. Ryan D. Chavez, CFO & Gen. Counsel (Age 43)

How do I buy shares of Asterias Biotherapeutics?

Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

How big of a company is Asterias Biotherapeutics?

Asterias Biotherapeutics has a market capitalization of $0.00. View Additional Information About Asterias Biotherapeutics.

What is Asterias Biotherapeutics' official website?

The official website for Asterias Biotherapeutics is http://asteriasbiotherapeutics.com/.

How can I contact Asterias Biotherapeutics?

Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805.


MarketBeat Community Rating for Asterias Biotherapeutics (NYSEAMERICAN AST)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  131 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  249
MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe AST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel